Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study

(2018) Norikazu Masuda et al.   CANCER SCIENCE

Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma

(2018) Marie Shimanuki et al.   Oncotarget

Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project

(2017) Koshi Nakamura et al.   JOURNAL OF EPIDEMIOLOGY

462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS

(2017) W. Sun et al.   ANNALS OF ONCOLOGY

116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2-) metastatic breast cancer (mBC)

(2016) S-A. Im et al.   ANNALS OF ONCOLOGY

Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients

(2016) Kenji Tamura et al.   CANCER SCIENCE

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)

(2016) Sunil Verma et al.   ONCOLOGIST

The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

(2016) Tomohiko Aihara et al.   Breast Cancer

Risk Factors for Predicting Severe Neutropenia Induced by Pemetrexed Plus Carboplatin Therapy in Patients with Advanced Non-small Cell Lung Cancer

(2015) Hiroaki Ikesue et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

(2015) W. Hu et al.   CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

(2014) F. Cardoso et al.   ANNALS OF ONCOLOGY

Average Values and Racial Differences of Neutrophil Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects

(2014) Basem Azab et al.   PLoS One

Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes

(2011) Navin Pinto et al.   CURRENT DRUG METABOLISM

Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer

(2008) P. Jenkins et al.   ANNALS OF ONCOLOGY

Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations

(2008) SP Myrand et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

White Blood Cell Count, Especially Neutrophil Count, as a Predictor of Hypertension in a Japanese Population

(2008) Yoshimi TATSUKAWA et al.   HYPERTENSION RESEARCH

PhRMA White Paper on ADME Pharmacogenomics

(2008) J. Andrew Williams et al.   JOURNAL OF CLINICAL PHARMACOLOGY